BJH - volume 12, issue 6, october 2021
C. Schuermans MD, D. Mazure MD, K. Van Eygen MD, L. Van Aelst MD, PhD, S. Benghiat Fleur MD, PhD, T. Devos MD, PhD
Polycythemia vera (PV) is classified by the World Health Organization (WHO) under the BCR-ABL-negative myeloproliferative neoplasms (MPNs) and is characterised by clonal proliferation of myeloid cells, which leads primarily to an increased red blood cell mass. Bone marrow morphology remains the cornerstone of diagnosis. Patients can present with thrombosis, microcirculatory symptoms, haemorrhage, splenomegaly, pruritus and other symptoms that reduce their quality of life and they are at risk of transformation to secondary myelofibrosis (MF) or acute myeloid leukaemia (AML). The main goal of therapy in PV is to minimise the thrombotic risk. To achieve this goal PV patients are being treated with low-dose aspirin and phlebotomies to reach a target haematocrit below 45%. In addition, high-risk patients are being treated with cytoreductive agents. Over the last years, new insights in the pathophysiology, diagnosis and prognosis of polycythemia vera were acquired and novel therapeutic options are available. In this paper we give an update on PV and provide diagnostic and therapeutic recommendations, taking into account the Belgian situation.
(BELG J HEMATOL 2021;12(6):258-74)Read more
BJH - volume 11, issue Abstract Book BHS, february 2020
K. Kehoe , S. Weekx , S. Vermeiren , K. Ver Elst , T. Eyckmans MD, C. Schuermans MD, J. Lemmens MD
BJH - volume 10, issue 5, september 2019
C. Schuermans MD
At the EHA annual meeting of 2019, interesting new data with regard to myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) were presented. For patients with high-risk myelofibrosis (MF) who have failed or are intolerant to ruxolitinib (rux) as well as for patients with higher risk MDS, the prognosis is poor and treatment options are few. There is still a large unmet medical need for these patient groups and new therapies are eagerly awaited. The same holds true for patients with advanced systemic mastocytosis (AdvSM). For this patient group very promising data about a new inhibitor of KIT D816V were presented. In contrast, most chronic myeloid leukemia (CML) patients have a much brighter outlook with the currently available tyrosine kinase inhibitors (TKI) treatments and some can even stop their TKI and have a durable treatment-free remission (TFR). A short update of the DASFREE and ENESTfreedom data will be discussed below. Some CML patients however do not reach their treatment goals and are waiting for new treatment options. Also data on pregnancy outcomes in CML patients were discussed.
(BELG J HEMATOL 2019;10(5):188–94)Read more
BJH - volume 7, issue Abstract Book BHS, january 2016
M. Criel , F. Declau , C. Schuermans MD, K. Ver Elst , S. Vermeiren , S. Weekx , J. Lemmens MD
BJH - volume 4, issue 4, december 2013
T. Devos MD, PhD, N. Straetmans MD, PhD, C. Schuermans MD, S. Benghiat MD, PhD, V. Robin MD, P. Lewalle MD, PhD, P. Mineur MD, G. Verhoef MD, PhD, L. Knoops MD, PhD
Diagnostic and management guidelines for myelofibrosis patients are presented in this paper. As a consequence of the rapid evolution and progress in this domain over the last years, the need was felt by the BHS MPN subcommittee to update these guidelines for our country. The different prognostic scores in myelofibrosis, the diagnostic tools and treatment options with the focus on new possibilities are discussed.
(BELG J HEMATOL 2013;4(4): 127–137)Read more
BJH - 2013, issue BHS Abstractbook, january 2013
J. Caers MD, PhD, M-C. Vekemans MD, PhD, I. Vande Broek MD, PhD, P.H. Mineur , K. Beel MD, PhD, V. Maertens MD, C. Schuermans MD, F. Leleu , G. Vanstraelen , H. Demuynck MD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD, G. Bries MD, PhD, A. Van De Velde MD, M. Delforge MD, PhD, C. Doyen MD, PhD